Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
about
Different anthracycline derivates for reducing cardiotoxicity in cancer patientsDifferent anthracycline derivates for reducing cardiotoxicity in cancer patientsPalmar-plantar erythrodysesthesia associated with chemotherapy and its treatmentCardiotoxicity in childhood cancer survivors: strategies for prevention and managementA Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerBreast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesNanoparticle-mediated drug delivery for treating melanomaEfficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled TrialsNanotechnology: Future of OncotherapyCancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.Cardiac toxicity in cancer survivorsTreating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristineDelivery of gene silencing agents for breast cancer therapyMultifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilitiesUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)Enhanced Specificity and Drug Delivery in Tumors by cRGD-Anchoring Thermosensitive LiposomesThe potential of polymeric micelles in the context of glioblastoma therapy.Liposomes as nanomedical devicesEffects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivoTowards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancerNanotechnologies for noninvasive measurement of drug releaseMilk derived colloid as a novel drug delivery carrier for breast cancerChemophototherapy: An Emerging Treatment Option for Solid TumorsTargeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imagingTumor endothelial cell-specific drug delivery system using apelin-conjugated liposomesModulation of vincristine and doxorubicin binding and release from silk filmsIncidence and implications of chemotherapy related hand-foot syndrome.Cancer drug related cardiotoxicity during breast cancer treatment.Cancer treatment-related cardiac toxicity: prevention, assessment and management.Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.Clinical Translation of Nanomedicine.Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems.Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Point-of-Care Technologies for the Advancement of Precision Medicine in Heart, Lung, Blood, and Sleep Disorders.Synthesis and characterisation of ultrasound imageable heat-sensitive liposomes for HIFU therapy.Fiber-optic triggered release of liposome in vivo: implication of personalized chemotherapy.Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model.Development and optimization of a doxorubicin loaded poly(lactic acid) contrast agent for ultrasound directed drug delivery.Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.
P2860
Q24235507-596BC949-1715-4FBE-B92E-F78C06B4A672Q24236622-BB96FEA8-EEC9-4BE2-AD49-BC399F95FAF3Q24604735-AEFB23CD-F432-478C-90CA-F2D46C25B7D9Q24628695-F1E91E07-99BD-4C78-BE63-F5400FCE39AFQ26752846-507E9CF8-C170-488F-AF14-9A9F760D0C92Q26783705-BBE56DEF-6889-4E7A-9334-1E1C61817F8BQ26798379-B259D0CB-4B43-4014-9C89-B3F63EEE80BCQ26800140-A73289FF-30C4-4854-83FA-370582FF931FQ26801067-45898E7C-6C1A-4249-9327-35F22C0FC32BQ26830028-EF468B2F-4AEF-4C10-A7AB-50299878451AQ26851957-B577BF1A-AACB-46D7-AC1F-882E19CB2E32Q27000078-5236E5E8-B990-4350-9DE4-4F1E058AB06BQ27008706-06FA640E-7313-4412-8140-931CF3038C51Q27011598-24F140CE-1A60-4AEB-861F-1D722A23B483Q27027354-01B19CB4-63E3-4C9F-9009-9025AAD27491Q27300391-25C29D9A-23C4-4091-A6DF-FDDBB846B9DCQ27314854-651AD178-2555-4CF9-8575-1E353100DA3CQ27693205-A382EA68-7ABC-40F0-BA5E-8D93F9AF4CD9Q28088315-62BC21DC-5E5F-47B4-87B1-908F02E70D13Q28258783-A412087D-8600-452B-AF6D-BCA0341D2749Q28291499-F60974FE-998D-46E1-9DAA-CC6946617496Q28387499-3FF5C3C3-BB88-47FC-8127-9A992A275F37Q28392295-C20916A4-75EC-4129-8ED1-93A747832D4FQ28468315-CE153BC0-9FBE-4656-9469-FA89C4143594Q28533782-34EA1998-F5DA-4FB0-AD12-54C675416503Q28533945-8AF67722-9856-48C4-9210-6243B8147563Q28829218-1602C876-F6C9-465B-AD99-67DD52EFBF2BQ30244770-B343025F-ADCD-433C-8242-30AF11626C41Q30251498-12307E2D-8877-482D-A50E-D20269657502Q30276456-A1918412-03A6-4289-AA88-655CA0C1FB5FQ30279055-B0F01839-8902-46EC-9BF7-5CFA1CC3A13EQ30355939-9AC3FB8A-0D6A-45C2-B6D3-41A8416BF2A8Q30361646-162CC401-5DB4-49ED-853A-D37ADD7EE2F4Q30366990-D9C0AE03-566B-4747-BC00-C3138681D918Q30374876-4D3F3A29-0EAC-46D8-A187-3A5A9997D5FDQ30375252-3B0A090D-8C26-44D5-A7B2-638D9757719BQ30404334-2FD8779E-EC84-4D9E-8A40-94544E2480A7Q30456019-2E8F6ACD-A565-40E7-A9FD-39E92264ECE4Q30475985-46F8D91B-CDEC-4DFD-A0CD-F67F8F01E480Q30583249-4B84BBA3-68AA-4FC6-AA06-17B3FA02A8C7
P2860
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Reduced cardiotoxicity and com ...... t of metastatic breast cancer.
@ast
Reduced cardiotoxicity and com ...... t of metastatic breast cancer.
@en
Reduced cardiotoxicity and com ...... ated liposomal doxorubicin HCl
@nl
type
label
Reduced cardiotoxicity and com ...... t of metastatic breast cancer.
@ast
Reduced cardiotoxicity and com ...... t of metastatic breast cancer.
@en
Reduced cardiotoxicity and com ...... ated liposomal doxorubicin HCl
@nl
prefLabel
Reduced cardiotoxicity and com ...... t of metastatic breast cancer.
@ast
Reduced cardiotoxicity and com ...... t of metastatic breast cancer.
@en
Reduced cardiotoxicity and com ...... ated liposomal doxorubicin HCl
@nl
P2093
P356
P1433
P1476
Reduced cardiotoxicity and com ...... t of metastatic breast cancer.
@en
P2093
CAELYX Breast Cancer Study Group
D G Kieback
E Grischke
M E R O'Brien
P304
P356
10.1093/ANNONC/MDH097
P577
2004-03-01T00:00:00Z